EyePoint Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 15.2 million compared to USD 10.01 million a year ago. Net loss was USD 12.61 million compared to USD 18.42 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.49 a year ago.
For the nine months, revenue was USD 31.99 million compared to USD 30.87 million a year ago. Net loss was USD 56.7 million compared to USD 58.8 million a year ago. Basic loss per share from continuing operations was USD 1.5 compared to USD 1.58 a year ago.